{
  "abstract": "The National Institute for Health and Care Excellence (NICE) has recommended darolutamide in combination with androgen deprivation therapy (ADT) as a treatment option for patients with metastatic hormone sensitive prostate cancer unsuitable for chemotherapy.",
  "authors": [
    {
      "affiliations": [
        "Kent"
      ],
      "name": "Jacqui Wise"
    }
  ],
  "title": "Prostate cancer drug: NICE approves better tolerated combination for advanced cases",
  "uid": "30470e12-5f07-5a91-ad1f-3d3343dbe931"
}